If, like us, you are appalled by Russia's aggression against Ukraine and inspired by the bravery of the Ukrainian people, please sign on to our commitment to sever financial ties with the Russian government and economic elite.

Members of TechAtlas work closely with the Investment Team and our portfolio companies to put data into context, identify breakthroughs, and develop conviction about how to solve particular problems given what we know of all the different technologies in development.

Gateway is RA Capital’s new board-building tool. It’s free to use, so give it a try. And if you’re on a biotech board or aspire to be on one, please take a minute to fill out a profile.

Ah, the American Old West. Where the buffalo roamed, cowboys fought, and Coke still had cocaine. A LOT of things had cocaine. Only the most vigilant and educated physician or pharmacist could hope to keep harmful or useless drugs off their shelves. And if we can still find physicians prescribing ivermectin for COVID today, imagine how hard finding reliable information must have been back then. 

Take a few minutes at the beginning of a board meeting to give the board the big picture before asking them to analyze individual pieces of your narrative. At RA Capital, we encourage our companies to use a tool called the Elephant Slide. This slide helps visualize a company’s value proposition, goals, challenges, and upcoming decisions in one place - allowing you to address the elephant in the room.

As a Swede who has lived in the United States for ~25 years, I’ve experienced two very different healthcare systems. As a child and young adult, I took free (or nearly free) healthcare for granted. However, when I left Sweden to pursue a graduate degree in the US, I was shocked to realize that the system here is very different. I learned new words like ‘deductible’ and ‘copay’ that were not previously part of my vocabulary.

GentiBio CEO Adel Nada discusses why biotechs should build organizations that allow the kind of “good” failures necessary for striking into the unknown and forming the foundations of success. To do so, we must foster cultures that prepare us for, and prepare us to learn from, the field’s inevitable setbacks.

The biotech job market is hotter than ever and it’s not likely to cool down in 2022. So if you’re thinking about joining the Great Resignation and jumping into a new role at a biotech startup, it’s crucial to learn how to think about valuing competing equity offers.

In case you missed it (or if you’d like to send a link to a colleague), we’ve compiled a list of RApport’s most popular stories of 2021, along with a few things we’ll be reading over our end-of-year break.

As the Omicron variant looms over this holiday season, an increasing number of companies are pushing back return-to-office plans (again). What does this mean for all of us? Another year of Zoom. And, Zoom, after spending almost two years “working” on your platform, I have some notes.

Growing emphasis on ESG may be a net positive, but how do individual companies allocate resources toward tracking, reporting, or implementing additional practices when those resources might be better spent on their core business that is inherently ESG-focused?

Biotech board members and management teams are increasingly asking how their companies can benefit from what RA Capital and others call a “Series I” IPO process (also known as a data-driven or logic-based IPO). Here we’ve compiled common questions and answers.

In this month’s episode, we discuss the latest COVID news. Then Peter Kolchinsky talks with our guest, Dr. Joshua Cohen of Tufts Medical Center, about how they estimate the value of a drug.

RA Capital teams swept first and second place in Inner City Weightlifting’s “2021 Fittest Company Challenge.” How’d we do it? Because our teams embodied so many of the values that make RA Capital great.

Covid has flooded a barren vaccine startup landscape with capital. And that has revealed some valuable lessons for investors, company builders, Congress, and the public.

As more established targeted protein degradation companies produce promising data in the clinic, newcomers have been greeted with sustained enthusiasm from the investment community. Here we revisit a few key intellectual and scientific breakthroughs & focus on molecular glues as an exciting new frontier.

The story of Alexander Fleming is a popular one. As it should be - it’s a good story about one of the most important discoveries in medical history, penicillin. But most people only know the first act of the play.

In this month’s episode of RA TV, we look back at the past year for biotech, examine today’s headlines, and contemplate the future of this pandemic — and maybe the next one.

LENZ Therapeutics CEO Eef Schimmelpennink spoke with RApport about how last year’s acquisition of Pfenex by Ligand gave him a chance to seek out a new challenge, the benefits of breaking the mold, and helping 120 million Americans ditch their reading glasses.

In biotech - an industry where companies live or die by the success of a lead asset - how much impact does a successful management team have? And more broadly, how should we define success? Is it a matter of stock price? The ability to drive an acquisition? Do your employees even like you as a person?